14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MAZE vs MLTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Maze Therapeutics, Inc. (MAZE) is the stronger overall head-to-head candidate over MoonLake Immunotherapeutics Class A (MLTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MAZE carries a Unified Composite Score of 34.8/100 (SELL) at $34.16 (8.5x Forward P/E, -820.8% operating margin), whereas MLTX carries 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While MLTX currently prints a higher short-term Unified Composite Score (38.3/100 SELL vs. MAZE 34.8/100 SELL), MAZE captures the overall institutional head-to-head verdict (6–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-820.8% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Defensive Composite Rating Caution: Although MAZE compares more favorably head-to-head, both MAZE (34.8/100 SELL) and MLTX (38.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: MAZE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.6); meanwhile MLTX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MAZE vs MLTX. Trailing 12-month operating profitability (MAZE -820.8% vs MLTX 0.0%) and valuation multiples (MAZE 8.5x vs MLTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MAZE vs MLTX Key Questions & Quantitative Answers
As of Nov 16, 2026, Maze Therapeutics, Inc. (MAZE) is the stronger overall head-to-head candidate over MoonLake Immunotherapeutics Class A (MLTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MAZE carries a Unified Composite Score of 34.8/100 (SELL) at $34.16 (8.5x Forward P/E, -820.8% operating margin), whereas MLTX carries 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MLTX currently prints a higher short-term Unified Composite Score (38.3/100 SELL vs. MAZE 34.8/100 SELL), MAZE captures the overall institutional head-to-head verdict (6–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-820.8% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Defensive Composite Rating Caution: Although MAZE compares more favorably head-to-head, both MAZE (34.8/100 SELL) and MLTX (38.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MAZE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.6); meanwhile MLTX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MAZE leads the Growth & Scale pillar: MAZE posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $20M TTM revenue (100.0% gross margin, -820.8% operating margin), compared with MLTX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MAZE generates $20M in USD-normalized revenue versus N/A for MLTX. In operating R&D and SG&A reinvestment, MAZE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MLTX.
MAZE screens cheaper on headline valuation multiples. MAZE trades at 8.5x Forward P/E, 8.5x Trailing P/E, N/M PEG, and 98.7x EV/Revenue (unreported EBITDA margin), whereas MLTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MAZE (-37.5% ROE) versus MLTX (-81.5% ROE) capital efficiency.
In options market volatility and institutional positioning, MAZE carries 96.4% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.78β · 54% Vol realized risk). By comparison, MLTX carries 111.8% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.61β · 90% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.